- US500 remains at 23-month highs ahead of the Fed decision
- USD Dollar holds off significant movements
- Pfizer warns that company revenues may decline in 2024
- Vertex jumps after positive results in pain medication study
Wall Street is holding its breath at the opening of the cash session on Wednesday. The indices are recording moderate increases up to 0.30%. Nevertheless, they remain at 23-month highs. Similar behavior can be observed in the forex market, where the USD Dollar is moderately calm. On the USD Dollar index (USDIDX), we see consolidation over the week. The yields on 10-year US bonds are falling and currently stand at 4.17%.
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile appAfter the recent deeper correction, the USD Dollar has halted its decline around 102.3 points. Although the dollar began to strengthen again since the end of November, the increases have stopped at the 38.2% Fibonacci retracement around 104.4 points. Today's publication of the Fed's decision on interest rates and the speech by Chairman Jerome Powell will be crucial in determining the trend for the coming weeks. Source: xStation 5
US500 is trading today around yesterday's closing prices. The index gains a modest 0.05%. However, the quotes remain at 23-month highs, above the local mid-year peak of 4630 points. Definitely, the entire market's attention is focused on the last conference and the FOMC's decision this year. The market will be looking for clues in Chairman Jerome Powell's speech regarding the prospect of the first interest rate cuts. Source: xStation 5
Company news
Pfizer (PFE.US) shares dropped almost 10% after the company projected a revenue decline for 2024, citing reduced demand for its Covid-19 vaccine and related products. The forecasted revenue of $58.5 billion to $61.5 billion falls short of analysts' expectations of $62.66 billion. This downturn is attributed to overestimation of Covid-19 vaccine and drug sales, which had previously boosted Pfizer's performance during the pandemic. The company anticipates around $8 billion in revenue from its Covid-19 vaccine and Paxlovid treatment next year, down from this year's expected $12.5 billion. Amidst this, Pfizer is focusing on growth in operational revenue and has announced a major $43 billion deal for Seagen, aiming to establish a separate cancer-drug business. The company's adjusted earnings forecast for 2024 is also lower than analysts' predictions.
Pfizer's share price today dips to its lowest level since 2013, not including a one-day drop during the Covid-19 pandemic in 2020. Source: xStation 5
Vertex Pharmaceuticals (VRTX.US) experienced a 7.0% increase in premarket trading following the announcement of positive results from a Phase 2 study of VX-548, their investigational non-opioid drug for treating painful diabetic peripheral neuropathy. The study showed a significant and clinically meaningful reduction in pain, as measured by the Numeric Pain Rating Scale. The company highlighted the potential of VX-548 to become a new class of medicine for millions suffering from neuropathic pain. The drug was generally well-tolerated in the study, and Vertex plans to move forward with pivotal development after discussions with regulators.
Source: xStation 5
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
